Skip to Content
Morningstar

Sanofi Adds Diabetes Drug With Provention Bio Deal

""
Securities In This Article
Sanofi SA ADR
(SNY)

Sanofi’s SNY announced acquisition of Provention Bio adds new diabetes drug Tzield to Sanofi’s entrenched cardiometabolic platform. However, we don’t see the nearly $3 billion deal as significantly affecting Sanofi’s fair value estimate or wide moat.

We believe the deal largely centered on Provention Bio’s type 1 diabetes-delaying drug Tzield. With a price point of close to $200,000 and over 60,000 people being diagnosed each year in the U.S. (according to the JDRF), the market potential for the drug is very large. Also, the drug was shown to delay progression to stage 3 type 1 diabetes from stage 2 by close to two years. We believe this efficacy will support enough market share gains to enable peak annual sales of Tzield of close to $1 billion annually. However, we believe the sales ramp-up of the drug will be slower, as the physician community will likely need heavy education and marketing given the uniqueness of the drug and the new mechanism of action (CD3-directed antibody). Additionally, with the drug just gaining approval in the U.S. in November 2022, we expect reimbursement challenges due to the high price point, which may slow the near-term launch trajectory.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

MORN DODFX VINIX VWILX TSVA EGO WU Brightstart429plan MRO VZ MOAT T NKE CMCSA GOOG

More in Stocks

About the Author

Damien Conover, CFA

Sector Director
More from Author

Damien Conover, CFA, is the director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar’s investment philosophy by working closely with the firm’s sector strategists and directors.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Damien Conover, CFA, is the director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar’s investment philosophy by working closely with the firm’s sector strategists and directors.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

Sponsor Center